Drug
Treprostinil Palmitil
Treprostinil Palmitil: highest development phase Phase 2/3, developed by Insmed. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Insmed
Trials
| Drug | Phase | Indication |
|---|---|---|
| Treprostinil Palmitil NCT05649748 | Phase 2/3 | Pulmonary Arterial Hypertension |
| Treprostinil Palmitil NCT05147805 | Phase 2 | Pulmonary Arterial Hypertension |
| Treprostinil Palmitil NCT05176951 | Phase 2 | Pulmonary Hypertension |
| Treprostinil Palmitil NCT04791514 | Phase 2 | Pulmonary Arterial Hypertension |
Latest
No recent events.
Follow Treprostinil Palmitil on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.